IL22 and cancer: In addition, apart from other cytokines associated with cancer, IL-22 has been restricted to tissue targets and its receptor (IL-22R1) is particularly expressed on epithelial and tissue cells, but not on benign immune cells.   88  However, it is demonstrated that expression of IL-22R1 and autocrine IL-22 stimulation contribute to lymphoid malignancy and tumorigenicity in anaplastic large cell lymphoma (ALCL).        89  The expression of IL-22R1 in anaplastic lymphoma kinase-positive (ALK+) ALCL is aberrant, whereas this receptor is absent in benign lymphocytes.        90